Introduction
============

Epidemiologic surveys show that HIV transmission patterns have changed, shifting the epidemic towards the poorer, those living in non-urban areas and women. Increasing heterosexual transmission is responsible for the ever growing rates of infected women. Considering that 85% of infected women are within their reproductive years, the risk of mother-to-child transmission (MTCT) is significant \[[@B1]\].

In Brazil, a sentinel study (Estudo Sentinela-Parturiente) has shown that the prevalence of HIV infection among pregnant women is 0.41% and that HIV testing for pre-natal care is performed in only 62.3% of patients \[[@B2]\]. Out of 63 countries analyzed by UNAIDS, Brazil provides antiretroviral therapy for 50 to 75% of infected pregnant women \[[@B1]\]. MTCT rates were evaluated in a large multicentric study that found 8.6% of newborn infection in 2000 and 7.1% in 2001 \[[@B3]\].

Several factors have been implicated in MTCT of HIV, including: advanced maternal AIDS-related illness, elevated viral loads (VL), breastfeeding, route of delivery, other infectious and obstetrics conditions and low CD4 cell counts during pregnancy \[[@B4]-[@B7]\]. Furthermore, viral subtype \[[@B8]\], viral concentration in maternal genital fluids \[[@B9],[@B10]\] and genetic factors were also identified \[[@B11]\]. Short duration of antiretroviral therapy during the course of pregnancy, problems regarding adhesion to treatment \[[@B12]\] and coinfecctions such hepatitis C virus \[[@B13]\], genital herpes \[[@B14]\], cytomegalovirus \[[@B15]\], syphilis \[[@B16]\], toxoplasmosis \[[@B17],[@B18]\] and recreational drug abuse \[[@B19]\] further increase the risk of MTCT.

The beneficial role of antiretroviral therapy in decreasing the risk of MTCT of HIV has been largely documented, since ACTG 076 protocols were published \[[@B20]\]. The use of highly active antiretroviral therapy (HAART) prior to conception and its earlier initiation in the course of pregnancy was also associated with lower rates of transmission \[[@B12]\].

CAISM/UNICAMP has been involved in the treatment and care of HIV-infected pregnant women since 1988. A historical cohort of HIV infected pregnant women has shown reduction of MTCT rates from 32.3% in 1990 to 2.9% in 2000. The greatest decline was observed after the introduction of the complete recommendations of ACTG 076 protocol. At that time, there were no reported cases of MTCT in pregnant women treated with HAART \[[@B21]\].

The objectives of this study were to evaluate mother-to-child transmission of HIV and related factors, to describe clinical and epidemiological profile of HIV infected pregnant women in a specialized prenatal care facility from 2000 to 2009 and to identify possible consequences of maternal infection to the newborn infant.

Subjects and method
===================

Observational and analytical study, with a historical cohort constituted by a population of 452 HIV-infected pregnant women in the period of 2000 to 2009 receiving care at the institution. The women were retrospectively selected from clinical records and from the epidemiologic surveillance system. A specific form was developed for data gathering and the EPINFO program was used for data analysis. The following variables were analyzed: epidemiologic characteristics of the women (age, formal education, parity, planned pregnancy), clinical characteristics (previous use of HAART, previous diagnosis of HIV, CD4 cell count, viral load, regimens of antiretroviral treatment, maternal coinfecctions and gestational problems) and characteristics of the newborn (birth weight, birth length, Capurro, Apgar scores, neonatal morbidity and use of oral zidovudine).

All newborns exposed to HIV were referred to the Pediatric Immunodeficiency Service at the same University. In the few cases, where a final diagnosis of HIV infection in the newborn was not possible due to loss of follow up, the main caretaker was contacted by phone or mail. Research protocol was previously approved by the Institution Review Board (Project number 459/2004).

Statistical analysis was conducted regarding demographic and epidemiologic characteristics of the women, prenatal care, use of antiretroviral therapy, delivery and newborn. Data was analyzed through proportions distributions and means, comparatively between groups of HIV-infected and non-infected children. The specific effect of several different interventions was analyzed through their individual risk ratios (RR). Possible associations between each variable were further tested with qui-square test or Fisher\'s exact test. The association between continuous variables was tested through student *t*test (parametric data), Mann-Whitney test (non-parametric data) and ANOVA. The 95% confidence interval and the level of significance of 0.05 were used. Data was analyzed with the statistical program SAS version 9.1.

The association between maternal and perinatal variables and MTCT was evaluated with qui-square test, Fisher\'s exact test and calculation of risk ratio and confidence intervals to 95%. Multivariate analysis was performed according to the COX model for proportional risks (adjusted risk ratio). However, due to problem during mathematical convergence related to the actual absolute number of positive outcomes (mother-to-child transmission events), results in this front could not be measured.

The study protocol was approved by the Internal Review Board (IRB) of the Center for Women\'s Integrated Healthcare (CAISM), Department of Obstetrics and Gynecology, University of Campinas (UNICAMP) and by the IRB of the School of Medical Sciences of the same institution (approval letter \#459/2004).

Results
=======

Between 2000 and 2009, 26.668 deliveries occurred in the institution and 452 were from HIV-infected pregnant women, corresponding to a prevalence of 1.69% of all deliveries. Figure [1](#F1){ref-type="fig"} shows excluded cases in the final analysis, performed with 401 infants. Data referring to multiple gestations were not replicated. The analysis comprised 392 gestation events.

![**Mother-to-child transmission in HIV pregnant women from 2000 to 2009**.](1742-4755-8-35-1){#F1}

Characteristics of pregnant women, prenatal care and delivery
-------------------------------------------------------------

The characteristics of pregnant women are presented in Table [1](#T1){ref-type="table"}. The majority of them (243 in 389-62.5%) was not on antiretroviral therapy when they got pregnant. Among women already using antiretroviral drugs, the most common combination was two nucleoside reverse transcriptase inhibitors (NRTI) and one protease inhibitor (PI) or one non-nucleoside reverse transcriptase inhibitor (NNRTI). Ninety percent of women (295 in 328) reported good adhesion (95% or more of all HAART had been taken as prescribed, in two occasions) to treatment during pregnancy \[[@B22]\].

###### 

Characteristics of HIV-infected pregnant women from 2000 to 2009

  Characteristics                                   
  ------------------------------------------- ----- ------
  ***Age***                                         
  \< 20                                       35    8.9
  20 a 29                                     234   59.7
  ≥ 30                                        123   31.4
  ***Caucasian race***                        234   59.7
  ***Number of pregnancies***                       
  1-2                                         177   45.2
  ≥ 3                                         215   54.9
  ***Fixed sexual partner***                  263   76.9
  ***Planned pregnancy***                     73    21.8
  ***Use of contraceptive method***           214   62.9
  ***Previous HIV-infected child***           30    10.6
  ***HIV diagnosis***                               
  Before pregnancy                            215   55.1
  During pregnancy                            170   43.6
  ***Sexual contact transmission***           262   86.5
  ***CDC classification***                          
  1                                           102   26.2
  2                                           161   41.4
  3                                           72    18.5
  Not classified                              54    13.9
  ***First CD4 \> 350 cel/ml (for NAIVE)***   137   39.1
  ***VL \< 50(copies/ml) after HAART***       93    53.1
  ***Efavirenz exposition***                  41    10.5
  ***Total***                                 392   100

\(#\) The numbers are different because of lack of informations from some patients

The mean number of prenatal visits was 7 (ranging from 1 to 18). Mean gestational age at the beginning of prenatal care was 18.1 weeks (ranging from 3 to 38). The majority of women (273 in 392-69.6%) presented at least one obstetric complication: preterm labor (14.5%), intrauterine growth restriction (6.1%) and chronic or gestational hypertension (5.1%) among others. Two hundred ninety nine in 392 (76.3%) had also at least one other infectious complication: bacterial vaginosis (32.9%), urinary tract infection (27%) and papilomavirus/intracervical neoplasia (22.7%) were the most prevalent. Resistance testing was performed only in 14 of 392 pregnant women (3.6%) by clinical indication (good adhesion and elevated viral load after two months of therapy). These patients were found to be carrying multiresistant HIV.

Prophylactic antiretroviral therapy (maternal CD4 \> 350 for naive) was used in 39.1% (137 in 350). Only eleven in 392 women (2.8%) did not use antiretroviral therapy during pregnancy by late diagnosis; 41 in 384 (10.5%) were exposed to efavirenz. Zidovudine monotherapy was used by 28 in 384 women (7.3%) and in 21 patients, it was maintained until birth. ART combinations used are presented in Table [2](#T2){ref-type="table"}. Mean CD4 cell-count was 474 cells/ml. Mean duration of antiretroviral therapy during pregnancy was 142.4 days. After HAART with PI, 66 pregnant women (71.7%) had undetectable viral loads. Three hundred and seventy in 380 cases (97.4%), intravenous zidovudine was used during labor and delivery.

###### 

Association between HAART combinations during pregnancy and newborn infection

  Newborn infection            With   Without   P\*   RR     IC 95%                  
  ---------------------------- ------ --------- ----- ------ ------------ ---------- ---------------
  **Antiretroviral therapy**                                 **0.0478**              
  AZT Monotherapy              3      14.3      18    85.7                1.00       
  NRTI+NRTI                    0      0.0       14    100                 NC         
  NRTI+NRTI+NVP                5      3.9       124   96.1                0.27       0.07-1.05
  NRTI+NRTI+NFV                3      2.3       125   97.7                **0.16**   **0.04-0.63**
  NRTI+NRTI+LPV/R              1      1.6       63    98.4                **0.11**   **0.01-0.99**
  Other PI regimens            1      4.3       22    95.7                0.30       0.03-2.70

\(#\) Missed information for 13 cases in 392 gestation events

(\#\#) NC: not calculated

(\#\#\#) No antiretroviral: 11 cases; 2 cases with newborn infection

Mean gestational age at birth was 37.2 weeks. In 92% (357 in 388) of cases, delivery was conducted by caesarean section, mainly indicated by HIV infection.

Characteristics of the newborns
-------------------------------

Of 401 newborns, 208 (52.9%) were female. Mean birth weight was 2820 g and mean birth age by the method of Capurro was 37.6 weeks. Seventy nine children were premature (24%) and 87 (21.96%) had low birth weight. Neonatal use of oral zidovudine in the hospital was confirmed in 100% of cases.

Twenty one children presented with major congenital malformations among 48 in 393 (12.2%) presenting with any malformation: 9 cases of cardiac anomaly, 7 cases of genital tract malformations and 5 cases of urinary tract malformations. The remaining cases comprised minor malformation such as supernumerary finger, auricular appendage, among others.

Thirty four in 382 children (8.9%) presented at least one other illness during neonatal period (12 cases of pneumonia, 10 cases of hepatitis C, 6 cases of candidiasis and toxoplasmosis, 4 cases of cytomegalovirus infection, hepatitis B and urinary tract infection, 3 cases of meningitis and sepsis, 2 cases of syphilis and one case of rubella, varicela and tuberculosis).

Factors associated with mother-to-child transmission of HIV
-----------------------------------------------------------

MTCT of HIV occurred in this cohort in 3.74% of cases. Risk factors identified for transmission were: low CD4 cell count, maternal AIDS-related illness, reduced time on HAART, obstetric and infectious concurring illnesses, presence of labor, neonatal coinfecctions, low birth weight, newborns small for gestational age, fail to complete postnatal prophylactic use of oral AZT and maternal and newborn anemia.

Any concurring AIDS-related illness during prenatal care enhanced the risk of transmission in around 5 times; maternal anemia (hemoglobin level under 11 g/dl) increased the risk of transmission in 4 times and also in cases of intrauterine growth restriction. Ovular infection elevated the risk in more than 21 times; neurotoxoplasmosis by itself increased it in more than 7 times (Table [3](#T3){ref-type="table"}).

###### 

Maternal factors associated and mother-to-child transmission of HIV

  ------------------------------------------------------------------------------------------------------------
  VARIABLES                           MTCT\   MTCT\     P\*   RR     IC 95%                   
                                      With    Without                                         
  ----------------------------------- ------- --------- ----- ------ ------------ ----------- ----------------
  **AIDS-related illness**                                           0.0748                   

  Yes                                 2       14.3      12    85.7                **4.87**    **1.19-19.93**

  No                                  11      2.9       364   97.1                1.00        

  **First CD4 (cel/ml)**                                             **0.0029**               

  ≥ 350                               1       0.5       212   95.5                1.00        

  \< 350                              8       5.8       129   94.2                **12.44**   **1.57-98.35**

  **Time using HAART**                                               0.0632                   

  15 days or longer                   11      3.1       342   96.9                1.00        

  Less than 15 days                   2       16.7      10    83.3                **5.35**    **1.33-21.53**

  **Ovular infection**                                               **0.0035**               

  Yes                                 2       66.7      1     33.3                **21.61**   **8.15-57.29**

  No                                  12      3.1       377   96.9                1.00        

  **Neurotoxoplasmosis**                                             **0.0127**               

  Yes                                 1       25        3     75                  **7.46**    **1.26-44.23**

  No                                  13      3.4       375   96.6                1.00        

  **Route of delivery**                                              **0.0190**               

  Vaginal                             4       12.9      27    87.1                1.00        

  Caesarean                           10      2.8       347   97.2                **0.22**    **0.07-0.65**

  **Labor**                                                          **0.0088**               

  Yes                                 6       9.8       55    90.2                **4.54**    **1.58-13.04**

  No                                  7       2.2       316   97.8                1.00        

  **Time after ruptured membranes**                                  0.5936                   

  Less than 4 hours                   2       11.1      16    88.9                1.00        

  \> 4 hours                          3       8.1       34    91.9                0.73        0.13-3.99

  No                                  10                328                                   

  **IV AZT**                                                         0.3126                   

  Yes                                 12      3.5       362   96.5                0.35        0.05-2.40

  No                                  1       10.0      9     90                  1.00        

  **Anemia (Hb level \< 11 g/dl)**                                   **0.0254**               

  Yes                                 4       11.8      30    88.2                **4.21**    **1.40-12.72**

  No                                  10      2.8       348   97.2                1.00        
  ------------------------------------------------------------------------------------------------------------

\(#\) The numbers are different because of lack of informations from some patients

First CD4 cell count during prenatal care was different among cases associated with transmission of HIV (219.1 cells/ml) and those not associated with it (480.9 cells/ml) (p = 0.002). Values lower than 350 cells/ml increased the risk of MTCT in more than 12 times (Table [3](#T3){ref-type="table"}).

During gestation, use of HAART constituted protective factor against MTCT of HIV, with difference attributed to the mean duration of use in days among cases of transmission (93.2 days) and those without transmission (144.2 days) (p = 0.0121). HAART use for less than 15 days prior to delivery determined and increased risk of transmission of more than 5 times (Table [3](#T3){ref-type="table"}). The use of antiretroviral drugs during pregnancy was not associated with low birth weight (p = 0.0808) or premature birth (p = 0.43).

Caesarean operation has shown protection in the order of 80% against MTCT of HIV. In the other, delivery occurring after the onset of labor determined an increased risk of almost 5 times for transmission of HIV (Table [3](#T3){ref-type="table"}).

Children who were considered to be small for gestational age had an increased risk of almost 5 times for HIV infection. Mean values of birth weight was different in cases of transmission of HIV (2416 grams) and those without (2836 grams) (p = 0.0392). Low birth weight was associated with an increase of 3 times or more in the risk of transmission. Children who did not receive oral zidovudine in the neonatal period had an increased risk of acquiring HIV of more than 35 times. Neonatal infections were significantly associated with mother-to-child transmission of HIV. Toxoplasmosis increased the risk in almost 24 times and cytomegalovirus infection in more than 15 times (Table [4](#T4){ref-type="table"}). Table [5](#T5){ref-type="table"} shows characteristics of HIV infected newborn and table [6](#T6){ref-type="table"} shows the mother-to-child-transmission rate year by year. The tendency is to a lower rate in the last years.

###### 

Neonatal factors associated with mother-to-child transmission of HIV

  VARIABLES                                                With   Without   P\*   RR     IC 95%                      
  -------------------------------------------------------- ------ --------- ----- ------ --------------- ----------- -----------------
  **Birth weight**                                                                       **0.0270**                  
  ≥ 2500 g                                                 8      2.8       301   97.2                   1.00        
  \< 2500 g                                                7      8.0       80    92                     **3.11**    **1.16-8.33**
  **Birth Weight in comparison to gestational age (GA)**                                 **0.0110**                  
  Adequate forGA                                           10     2.9       332   97.1                   1.00        
  Small for GA                                             5      13.2      33    86.8                   **4.50**    **1.62-12.48**
  **Oral AZT**                                                                           **0.0010**                  
  Yes                                                      11     2.8       381   97.2                   1.00        
  No                                                       2      100       0     0                      **35.64**   **19.90-63.81**
  **Neonatal pathology**                                                                 **0.0047**                  
  Yes                                                      5      14.7      29    85.3                   **5.67**    **2.01-15.96**
  No                                                       9      2.6       338   97.4                   1.00        
  **Congenital Toxoplasmosis**                                                           **\< 0.0001**               
  Yes                                                      4      66.7      2     33.3                   **23.94**   **10.63-53.93**
  No                                                       11     2.8       384   97.2                   1.00        
  **Pneumonia**                                                                          **0.0076**                  
  Yes                                                      3      25.0      9     75                     **8.10**    **2.63-25.02**
  No                                                       12     3.1       377   97.9                   1.00        
  **Congenital CMV**                                                                     **0.0075**                  
  Yes                                                      2      50.0      2     50                     **15.27**   **5.00-46.63**
  No                                                       13     3.3       384   96.7                   1.00        
  **Hepatitis B**                                                                        1.0000                      
  Yes                                                      0      0.0       4     100                    NC          
  No                                                       15     3.8       382   96.2                               
  **Syphilis**                                                                           1.0000          NC          
  Yes                                                      0      0.0       2     100                                
  No                                                       15     3.8       384   96.2                               
  **Anemia (hb \< 13,5 g/dl)**                                                           **0.0051**                  
  Yes                                                      8      8.7       84    91.3                   **5.83**    **1.58-21.46**
  No                                                       3      1.5       198   98.5                   1.00        
  **IUGR (intra uterine growth restriction)**                                            **0.0470**                  
  Yes                                                      3      12.5      21    87.5                   **4.18**    **1.25-14.00**
  No                                                       11     3.0       357   97                     1.00        
  **Hepatitis C**                                                                        1.0000                      
  Yes                                                      0      0.0       10    100                    NC          
  No                                                       15     3.8       376   96.2                               

\(#\) The numbers are different because of lack of informations from some patients

(\#\#) NC: not calculated

###### 

Charateristics of HIV infected newborns.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case     Year   PN\      Initial CD4   Final CD4   Final VL   ARV      Time ARV   Adhesion   IV\      AZT newborn   Ruptured membran   Route of delivery   Labor   Capurro   Birth Weight   Maternal\                Neonatal Pathology   Death
                  visits                                                                       AZT                                                                                            Pathology                                     
  -------- ------ -------- ------------- ----------- ---------- -------- ---------- ---------- -------- ------------- ------------------ ------------------- ------- --------- -------------- ------------------------ -------------------- -------
  **01**   00     10       \< 100        \-          \-         AZT      112        No         Yes      No            0                  Ces                 No      41        3370           No                       PCP                  Yes

  **02**   00     \-       \-            \-          \-         AZT      49         No         Yes      Yes           2 h                Vag                 Yes     36        2530           No                       Toxo                 No

  **03**   00     2        \-            \-          \-         AZT      40         No         Yes      Yes           0                  Ces                 Yes     40        3110           No                       Rubella              No

  **04**   01     8        \-            \-          \-         AZT      21         No         Yes      Yes           0                  Ces                 No      38        3230           No                       No                   No

  **05**   01     3        289           \-          \-         Haart    14         No         Yes      No            0                  Ces                 No      34        2635           No                       No                   No

  **06**   01     9        11            05          47000      Haart    260        No         Yes      Yes           1 h                Vag                 Yes     37        1985           Candid, PCP              Toxo                 Yes

  **07**   02     6        315           \-          420        AZT      10         No         Yes      Yes           **240 h**          Vag                 Yes     33        1320           Stevens-Johnson, Hep C   No                   No

  **08**   02     3        110           \-          17000      Haart    255        No         Yes      Yes           0                  Ces                 No      40        3000           Neurotox                 Toxo                 No

  **09**   03     5        344           \-          \< 50      Haart    140        **Yes**    Yes      Yes           0                  Ces                 Yes     40        3695           No                       No                   Yes

  **10**   04     6        424           630         1410       Haart    84         No         Yes      Yes           0                  Ces                 No      35        1340           No                       Oral cand.           No

  **11**   04     5        233           \-          \-         AZT      135        No         Yes      No            0                  Ces                 No      33        1705           No                       CMV                  No

  **12**   05     0        \-            \-          \-         **No**   0          No         **No**   No            63 h               Vag                 Yes     32        1425           No                       No                   No

  **13**   06     2        160           \-          \-         Haart    21         No         Yes      Yes           0                  Ces                 Yes     39        2790           No                       No                   No

  **14**   06     1        135           120         38380      Haart    \-         No         Yes      Yes           7 h                Ces                 Yes     37        2015           No                       First gemelar        No

  **15**   08     3        86            146         63         Haart    70         **Yes**    Yes      Yes           0                  Ces                 Yes     37        2100           Oral candid              Neurotoxo, CMV, TB   No
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Mother-to-child transmission of HIV by years of birth

  YEAR         With   Without   total          
  ------------ ------ --------- ------- ------ -----
  **2000**     3      13.6      18      86.4   22
  **2001**     3      6.1       46      93.9   49
  **2002**     2      3         65      97     67
  **2003**     1      2.5       39      97.5   40
  **2004**     2      3         40      97     42
  **2005**     1      3.1       31      96.9   32
  **2006**     2      4.4       44      95.7   46
  **2007**     0      0         37      100    37
  **2008**     1      1.9       51      98.1   52
  **2009**     0      0         12      100    12
  Total (\#)   15     3.7       384     96.3   399

\(#\) The numbers are different because of lack of information from some patients

Discussion
==========

The present study, analyzing 452 pregnancies from 2000 to 2009, found an HIV MTCT rate of 3.74%, which was above the expected for a reference maternity, in which nationally \[[@B23]\] and internationally accepted standard prophylactic measures are routinely employed in the care of HIV infected pregnant women. However, further studying of the 15 cases of transmission of HIV has shown particular results that explain such numbers. In spite of a multidisciplinary approach to prenatal care, with emphasis in medical (infectious disease specialist and obstetrician) and psychosocial care, the vast majority of mothers had substantial problems regarding adhesion to treatment and regular use of antiretroviral therapy prescribed during the gestation period. As a direct consequence of poor adhesion to treatment, some women reached delivery bearing high viral loads or even unknown values of viral load.

Our results shown several risk factors (low CD4 cell count, maternal AIDS-related illness, reduced time on HAART, obstetric and infectious concurring illnesses, presence of labor, neonatal coinfecctions, low birth weight, newborns small for gestational age, fail to complete postnatal prophylactic use of oral AZT and maternal and newborn anemia) associated with MTCT of HIV, confirming worldwide data on the subject \[[@B4]-[@B7],[@B12],[@B15],[@B17],[@B18]\].

Women with advanced degrees of imunossupression (CD4 \< 350 or AIDS) had a significantly higher risk of transmitting HIV to their newborns, similarly to results found in literature \[[@B4]-[@B7],[@B24]\].

HAART leads to undetectable viral load more rapidly in the course of treatment \[[@B12],[@B25]-[@B27]\]. HAART in comparison to AZT monotherapy was strongly associated with decreased risk of MTCT. Duration of antiretroviral therapy shorter than 15 days was associated with and increased risk, as was demonstrated by international study \[[@B12]\]. It is established that after two weeks of antiretroviral therapy the decrease in maternal viral load would be sufficient to decrease the risk of neonatal infection. Our data found that PI containing regimens were an important factor to protect against MTCT.

Preterm and low birth weight were not observed as complications of HAART use during pregnancy, in agreement with findings of other studies \[[@B28]-[@B31]\], but as opposite to what was concluded by others \[[@B32]-[@B34]\]. Thus, our results confirm the safety of antiretroviral drugs during pregnancy.

Obstetric and infectious complications of pregnancy have also lead to an increase in the risk of newborn HIV infection, in particular: anemia, intrauterine growth restriction and ovular infection. These factors can be symptomatic of compromised placental barrier function, increasing its permeability to HIV \[[@B35]\] and corroborate the importance of referring prenatal care of HIV infected pregnant women to tertiary specialized healthcare centers.

Great controversy still exists regarding the route of delivery in HIV infected pregnant women. Micro transfusions occurring during uterine contractions enhance blood exchanges between mother and fetus and the presence of significant viral load becomes an important factor in newborn HIV infection. Another issue presents itself as plasma viral load does not adequately represent viral concentrations in vaginal fluids \[[@B9]\]. So, even patients with sustained undetectable plasma viral load could still carry substantial viral load in vaginal secretions. Our data pointed out that the presence of labor has significantly increased the risk of MTCT.

This study demonstrated also, in concordance to current literature, a lower rate of MTCT following elective caesarean delivery, including women on potent antiretroviral therapy and with low peripartum plasma viral load \[[@B25],[@B36]\]. In fact, this has been the standard of care in this healthcare facility since 2005, provided that the patient did not present in advanced labor (elective caesarean delivery). Previous studies discussed the higher post partum morbidity in HIV pregnant women submitted to a caesarean section. However, recent studies did not find this association, leading to a relative safety by performing a caesarean in these women \[[@B25]\].

Premature rupture of membranes followed by vaginal delivery was present in one case of newborn infection, confirming it as a collaborating factor for MTCT \[[@B24],[@B35]\].

Low birth weight and small for gestational age also had increased risk for MTCT \[[@B37]\]. Among 15 infected newborns, in seven cases low birth weight was a contributing factor. Furthermore, several of these presented with serious infectious complications of the neonatal period. Maternal acute infections can compromise placental barrier, increasing the risk of MTCT. Several studies have demonstrated association, especially with maternal toxoplasmosis \[[@B17],[@B18]\] and CMV \[[@B15]\], reinforcing the need of exhaustive screening of these infections during prenatal care. Co-infection with hepatitis C occurred in more than 10% of cases, which can also enhance transmission of HIV \[[@B13]\].

There was one case of multiple gestation in which only the first to be born was infected. Although there is no known association between MTCT and multiple pregnancies after the use of HAART, the first newborn is more frequently infected \[[@B38]\].

Postnatal prophylaxis with oral zidovudine has demonstrated to be a significant factor in protection against neonatal HIV infection since ACTG 076 protocol \[[@B20]\], and our findings were similar.

This study demonstrates that MTCT was strongly associated with maternal factors such as the stage of HIV infection, represented by CD4 counts and viral load, use of HAART and route of delivery, and also factors regarding the gestational period, especially the presence of maternal infectious and obstetric complications. Regarding the newborn, use of neonatal zidovudine still poses as an important factor in the protection against HIV transmission.

One limitation of this study was the impossibility of multivariate analysis due to a limited number of infected newborns, which led us to interpretations based solely on risk ratios.

The increasing number of women infected with HIV observed over the past few years alerts to the importance of approaching the issue of MTCT as a serious public health problem. As a direct consequence of this are the emotional losses to these families and also the considerable financial expenses to both the public and private health system for the care and management of an incurable infection.

Our data demonstrate a high rate of MTCT. However it is strongly associated with poor adhesion to treatment of both HIV and concurring illnesses, to the presence of AIDS and other serious diseases. If only the cases in which newborn infection was in fact preventable were to be analyzed separately, it could be concluded that in one single case such scenario was true, in which all standard prenatal measures were implemented successfully leading to undetectable viral load prior to delivery.

The increasing number and complexity of cases reduce the quality of psychosocial and clinical support which, in turn, can influence adhesion to therapy and eventually lead to poor outcomes to the newborn. Thus, it becomes paramount for the HIV-infected pregnant women to be referred to a tertiary care center offering a multiprofessional approach aiming towards good adhesion to treatment and, ultimately, reducing mother-to-child transmission of HIV.
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